Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist

被引：0
|
作者：
Benjamin Berger
Jasper Dingemanse
Giancarlo Sabattini
Stéphane Delahaye
Urs Duthaler
Clemens Muehlan
Stephan Krähenbühl
机构：
[1] Idorsia Pharmaceuticals Ltd,Department of Clinical Pharmacology
[2] Idorsia Pharmaceuticals Ltd,Department of Preclinical Drug Metabolism and Pharmacokinetics
[3] University Hospital Basel,Division of Clinical Pharmacology and Toxicology
[4] University of Basel,Department of Biomedicine
来源：
Clinical Pharmacokinetics | 2021年 / 60卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1349 / 1360
页数：11
相关论文
共 50 条
  • [1] Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist
    Berger, Benjamin
    Dingemanse, Jasper
    Sabattini, Giancarlo
    Delahaye, Stephane
    Duthaler, Urs
    Muehlan, Clemens
    Kraehenbuehl, Stephan
    CLINICAL PHARMACOKINETICS, 2021, 60 (10) : 1349 - 1360
  • [2] Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, in patients with liver cirrhosis
    Berger, Benjamin
    Dingemanse, Jasper
    Sabattini, Giancarlo
    Duthaler, Urs
    Muehlan, Clemens
    Krahenbuhl, Stephan
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (SUPPL 1) : 3 - 3
  • [3] The metabolism of the dual orexin receptor antagonist daridorexant
    Treiber, Alexander
    Delahaye, Stephane
    Weigel, Aude
    Aeanismaa, Paivi
    Gatfield, John
    Seeland, Swen
    XENOBIOTICA, 2023, 53 (03) : 173 - 183
  • [4] Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, in patients with renal impairment
    Berger, Benjamin
    Muehlan, Clemens
    Klein, Gernot
    Dingemanse, Jasper
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (SUPPL 1) : 2 - 3
  • [5] Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
    Berger, Benjamin
    Muehlan, Clemens
    Klein, Gernot
    Dingemanse, Jasper
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (06): : 2132 - 2138
  • [6] Pharmacokinetics and Pharmacodynamics of the Dual Orexin Receptor Antagonist Daridorexant in Japanese and Caucasian Subjects
    Muehlan, Clemens
    Zuiker, Rob
    Peeters, Pierre
    Rowles, Racheal
    Dingemanse, Jasper
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2020, 40 (02) : 157 - 166
  • [7] Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
    Krause, Andreas
    Lott, Dominik
    Brussee, Janneke M.
    Muehlan, Clemens
    Dingemanse, Jasper
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (01): : 74 - 86
  • [8] The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin
    Zenklusen, Isabelle
    Muehlan, Clemens
    Ulc, Ivan
    Liska, Jiri
    Dingemanse, Jasper
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2020, 47 (11) : 1843 - 1849
  • [9] Daridorexant: A New Dual Orexin Receptor Antagonist for Insomnia
    St Onge, Erin
    Phillips, Bradley
    Rowe, Casey
    JOURNAL OF PHARMACY TECHNOLOGY, 2022, 38 (05) : 297 - 303
  • [10] THE DUAL OREXIN RECEPTOR ANTAGONIST DARIDOREXANT DOES NOT AFFECT THE PHARMACOKINETICS OF THE BCRP SUBSTRATE ROSUVASTATIN.
    Muehlan, C.
    Ulc, I.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S103 - S103
12345